The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
Pena MJ, de Zeeuw D, Andress D, Brennan JJ, Correa-Rotter R, Coll B, Kohan DE, Makino H, Perkovic V, Remuzzi G, Tobe SW, Toto R, Parving HH, Sharma S, Corringham T, Sharma K, Heerspink HJL.
Pena MJ, et al. Among authors: heerspink hjl.
Diabetes Obes Metab. 2017 May;19(5):749-753. doi: 10.1111/dom.12864. Epub 2017 Feb 22.
Diabetes Obes Metab. 2017.
PMID: 28019071
Clinical Trial.